# Foundayo vs. Wegovy: How These GLP-1 Medications Actually Differ
Two oral GLP-1 medications now compete for attention in weight management treatment. Wegovy (semaglutide) has dominated headlines since its FDA approval, but Foundayo (retatrutide) represents a newer class with a different mechanism. Understanding how they work helps patients and doctors make informed choices about which medication fits specific health needs.
Both medications target GLP-1 receptors in the brain and gut, but Foundayo does something Wegovy cannot. Foundayo is a triple hormone receptor agonist, meaning it activates GLP-1, GIP, and glucagon receptors simultaneously. Wegovy activates only the GLP-1 receptor. This difference matters for weight loss outcomes.
In clinical trials, retatrutide showed stronger weight reduction than semaglutide at comparable doses. Participants taking retatrutide at the highest dose lost approximately 24% of body weight, compared to roughly 22% for those on Wegovy. The gap widened at lower doses, where retatrutide's multi-receptor approach provided additional benefit. However, both medications require ongoing use. Patients who stop either drug typically regain weight within months.
Side effects present another consideration. Nausea, vomiting, and gastrointestinal issues occur with both medications but appear more common with retatrutide at higher doses. Some patients experience constipation severe enough to require intervention. These adverse effects often diminish over time as the body adjusts to treatment.
Cost and access shape real-world decisions. Wegovy has a longer track record and wider insurance coverage than the newly approved Foundayo. Many insurance plans still require weight loss documentation or specific BMI thresholds before covering either medication. Out-of-pocket costs can reach $1,000 monthly for either drug without insurance approval.
Doctors consider individual patient factors when choosing between these options. Patients with type 2 diabetes might benefit from Foundayo's glucagon receptor activation, which improves blood sugar control beyond what GLP-1 alone provides. Those seeking the most established treatment data may prefer Wegovy's longer history. Patients with severe gastrointestinal sensitivity might start with Wegovy's lower side effect profile at lower doses.
The injection versus pill distinction matters less than patients assume. Wegovy remains injectable only, while Foundayo comes as an oral tablet. This convenience factor appeals to many, but injection frequency differs between formulations. Some Wegovy patients inject weekly; others use different dosing schedules. Foundayo dosing similarly varies, and the perceived convenience of a pill doesn't guarantee better adherence if side effects emerge.
Neither medication works as a standalone treatment. Doctors consistently emphasize that successful weight management requires concurrent lifestyle changes. These drugs amplify the effects of dietary modification and physical activity. Patients who maintain structured eating and exercise regimens while taking either medication achieve better long-term outcomes than those who rely on medication alone.
As retatrutide becomes more widely prescribed, real-world data will clarify whether its superior trial results translate to sustained benefits in diverse populations. Both medications represent significant advances for patients who haven't succeeded with traditional weight loss approaches. The choice between them depends on individual medical history, insurance coverage, side effect tolerance, and specific health goals.